Events 11/16/23 「Announcement of “Japan-Korea Joint Symposium on Translational Research in Regenerative Medicine and Genome Editing”」

Event Information

Change log

15th November, 2023  The order of presentations in the program has been partially changed.

Summary of Event

Focusing on translational research in the field of regenerative medicine (including genome editing technology and cell therapy), which is a strength of both Japan and South Korea's life sciences, we will invite experts from both countries in the fields to introduce the latest research from both countries. In addition to introducing research & development trends and achievements, we will exchange opinions on possibilities for future cooperation between the two countries.

This symposium will be a hybrid event where you can participate either on site or online.


「Japan-Korea Joint Symposium on Translational Research in Regenerative Medicine and Genome Editing」

Date & Time

11/16/23 Thu 13:30-18:00[Opening: 13:00]


Nihonbashi Life Science Building Room#201(Nihonbashi Honcho, 2-3-11, Chuo-ku, Tokyo, 103-0023)


  • Online participation will be on a Zoom webinar. The URL will be provided to those who have registered to participate.


Onsite Participation: 100 people(Advance registration required: Registration will close once the capacity has been reached.
Online Participation: 500 people(Advance registration required: Registration will close once the capacity has been reached.



How to Apply

Please apply from the links below and choose to participate at the venue or online.
(Registration deadline: Tuesday, November 15th, noon)
Please note that registration will end as soon as the capacity has been reached.

Please register for the event, click here.


Japan Agency for Medical Research and Development (AMED)
The Korean Health Industry Development Institute (KHIDI)


The Japan Society of Gene and Cell Therapy (JSGCT)
The Japanese Society for Genome Editing (JSGE)
The Japanese Society for Regenerative Medicine (JSRM)
Life Science Innovation Network Japan (LINK-J)


Opening Remarks
Greetings from organizers and guests
President of AMED, President of KHIDI, MEXT
Mesenchymal stem cell derived extracellular vesicle therapy for liver cirrhosis. Prof TERAI Shuji
Graduate School of Medical and Dental Sciences Molecular and Cellular Medicine Cellular Function, Niigata University (Japan)
Developing iPSC-based cell therapy and drug screening for intractable neurological diseases Prof SONG Jihwan, Cha University Founder & CEO, iPS Bio, Inc (Korea)
iPSCs-based Regenerative Medicine for CNS Disorders Prof OKANO Hideyuki
Department of Physiology, Keio University School of Medicine (Japan)
Next-generation Cell Therapy: Human Pluripotent Stem Cell-derived Mesenchymal Stromal Cells Genetically Engineered to Express AFFIMER® Proteins to Enhance the Immune Response Dr RYU Jongsang, Chief Scientific Officer, AffyXell Therapeutics Co., Ltd. (Korea)
Precise Gene Editing in Rare Diseases Associate Prof BAE Sangsu, Seoul National University College of Medicine (Korea)
Genome editing and delivery technologies for muscular dystrophy Associate Prof HOTTA Akitsu
Department of Clinical Application, Center for iPS Cell Research & Application (CiRA), Kyoto University (Japan)
Application of the Genetically Humanized Mouse Model to the Development of Gene Editing Therapy Associate Prof SUNG YoungHoon, Convergence Medicine Research Center (CREDIT), Asan Institute for Life Sciences, Assan Medical Center/ Department of Cell and Genetic Engineering, University of Ulsan College of Medicine (Korea)
Swine in Biomedical Research Prof HANAZONO Yutaka
Translational Research Laboratory, Center for Development of Advanced Medical Technology, Jichi Medical University (Japan)
Panel Discussion Session


Japan-Korea Symposium Secretariat
Division of Strategic Planning
Department of International Strategy
Japan Agency for Medical Research and Development (AMED)

※Replace "at" with @".

Last updated 11/15/23